Role of serum cholinesterase in patients treated with salvage radical prostatectomy

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author VARTOLOMEI, Mihai Dorin
D'ANDREA, David
CHADE, Daher C. FMUSP-HC
SORIA, Francesco
KIMURA, Shoji
FOERSTER, Beat
ABUFARAJ, Mohammad
MATHIEU, Romain
MOSCHINI, Marco
ROUPRET, Morgan
BRIGANTI, Alberto
I, Pierre Karakiewicz
SHARIAT, Shahrokh F.
dc.date.issued 2019
dc.identifier.citation UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, v.37, n.2, p.123-129, 2019
dc.identifier.issn 1078-1439
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/30930
dc.description.abstract Background: Serum cholinesterase (ChE) a serine hydrolase that catalyses the hydrolysis of esters of choline, is involved in cellular proliferation and differentiation, therefore affecting carcinogenesis. The aim of this study was to understand the prognostic role of preoperative serum ChE in patients with radiation-recurrent prostate cancer (CaP) treated with salvage radical prostatectomy (SRP). Material and methods: This retrospective study included 214 patients with radiation-recurrent CaP treated with SRP from January 2007 to December 2015 at 5 academic centers. Patients were considered with abnormal/decreased ChE levels if <5 kU/l. Biochemical recurrence-free and metastases-free (MFS) survival analyses were performed. Results: Median serum ChE level was 6.9 (interquartile range) 6-7.7) kU/l. Serum ChE level (<5 kU/l) was decreased in 25 (11.7%) patients. Decreased serum ChE level was associated with lower body mass index (P = 0.006) and metastasis to lymph nodes (P = 0.004). In multivariable analysis, continuous ChE was an independent predictor of MFS (hazard ratio [HR] 0.48, confidence interval [CI] 0.33-0.71, P < 0.001), overall survival (HR 0.68, CI 0.48-0.96, P = 0.03) and cancer-specific survival (HR 0.41, CI 0.2-0.84, P = 0.01). Serum ChE improved the C-index (by 2.54%) to 87.8% for prediction of overall survival and (by 3%) to 92% for prediction of MFS. Conclusion: Preoperative serum ChE is associated with the development of metastasis in patients with radiation-recurrent CaP who underwent SRP. The biological underpinning of this association with the biological and clinical aggressiveness of CaP needs to be further elucidated.
dc.description.sponsorship · EAU (European Association of Urology)
· OeAD, Austria
dc.language.iso eng
dc.publisher ELSEVIER SCIENCE INC
dc.relation.ispartof Urologic Oncology-Seminars and Original Investigations
dc.rights restrictedAccess
dc.subject Radiation-recurrent; Prostate cancer; Salvage radical prostatectomy; Serum cholinesterase; Biomarker
dc.subject.other cancer; men
dc.title Role of serum cholinesterase in patients treated with salvage radical prostatectomy
dc.type article
dc.rights.holder Copyright ELSEVIER SCIENCE INC
dc.description.group LIM/55
dc.identifier.doi 10.1016/j.urolonc.2018.11.013
dc.identifier.pmid 30522902
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author CHADE, Daher C.:HC:ICESP
hcfmusp.author.external · VARTOLOMEI, Mihai Dorin:Med Univ Vienna, Dept Urol, Vienna, Austria; Univ Med Pharm Sci & Technol, Dept Cell & Mol Biol, Targu Mures, Romania
· D'ANDREA, David:Med Univ Vienna, Dept Urol, Vienna, Austria
· SORIA, Francesco:Med Univ Vienna, Dept Urol, Vienna, Austria
· KIMURA, Shoji:Med Univ Vienna, Dept Urol, Vienna, Austria; Jikei Univ, Dept Urol, Sch Med, Tokyo, Japan
· FOERSTER, Beat:Med Univ Vienna, Dept Urol, Vienna, Austria; Kantonsspital Winterthur, Dept Urol, Winterthur, Switzerland
· ABUFARAJ, Mohammad:Med Univ Vienna, Dept Urol, Vienna, Austria; Univ Jordan, Jordan Univ Hosp, Dept Special Surg, Div Urol, Amman, Jordan
· MATHIEU, Romain:Med Univ Vienna, Dept Urol, Vienna, Austria; Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
· MOSCHINI, Marco:Med Univ Vienna, Dept Urol, Vienna, Austria; Rennes Univ Hosp, Dept Urol, Rennes, France; Luzerner Kantonsspital, Klin Urol, Luzern, Switzerland; Univ Vita Salute San Raffaele, Urol Res Inst, San Raffaele Sci Inst, Dept Urol, Milan, Italy
· ROUPRET, Morgan:Sorbonne Univ, Paris, France
· BRIGANTI, Alberto:Univ Vita Salute San Raffaele, Urol Res Inst, San Raffaele Sci Inst, Dept Urol, Milan, Italy
· I, Pierre Karakiewicz:Univ Montreal, Dept Urol, Montreal, PQ, Canada
· SHARIAT, Shahrokh F.:Med Univ Vienna, Dept Urol, Vienna, Austria; Karl Landsteiner Inst Urol & Androl, Vienna, Austria; Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; Weill Cornell Med Coll, Dept Urol, New York, NY 10065 USA
hcfmusp.origem.id WOS:000454818000004
hcfmusp.origem.id 2-s2.0-85057561233
hcfmusp.publisher.city NEW YORK
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Bardal SK, 2011, APPL PHARM, P325, DOI [10.1016/B978-1-4377-0310-8.00021-X, DOI 10.1016/B978-1-4377-0310-8.00021-X]
· Battisti V, 2012, BIOMED PHARMACOTHER, V66, P249, DOI 10.1016/j.biopha.2011.11.005
· Bensalah K, 2008, PROSTATE CANCER P D, V11, P112, DOI 10.1038/sj.pcan.4501026
· Bradamante V, 2000, COLLEGIUM ANTROPOL, V24, P373
· Center KR, 2012, KRIG TXB PHARM
· Chade DC, 2012, EUR UROL, V61, P961, DOI 10.1016/j.eururo.2012.01.022
· Chade DC, 2011, EUR UROL, V60, P205, DOI 10.1016/j.eururo.2011.03.011
· Cornford P, 2017, EUR UROL, V71, P630, DOI 10.1016/j.eururo.2016.08.002
· Darvesh S, 2003, NAT REV NEUROSCI, V4, P131, DOI 10.1038/nrn1035
· Epstein JI, 2006, ADV ANAT PATHOL, V13, P57, DOI 10.1097/01.pap.0000202017.78917.18
· Gallina A, 2008, BJU INT, V101, P1513, DOI 10.1111/j.1464-410X.2008.07519.x
· Gelo Remigiusz, 2011, Anestezjol Intens Ter, V43, P33
· Gu SZ, 2005, WORLD J GASTROENTERO, V11, P4604, DOI 10.3748/wjg.v11.i29.4604
· Kaiser E, 1995, ANN FR ANESTH, V14, P505, DOI 10.1016/S0750-7658(05)80492-7
· Karam JA, 2007, PROSTATE, V67, P614, DOI 10.1002/pros.20557
· Koie T, 2016, INT J CLIN ONCOL, V21, P379, DOI 10.1007/s10147-015-0880-x
· Lughezzani G, 2010, EUR UROL, V58, P687, DOI 10.1016/j.eururo.2010.07.034
· Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361
· Mathieu R, 2017, BJU INT, V119, P234, DOI 10.1111/bju.13472
· Nair KK, 2017, J CLIN DIAGN RES, V11, pZC59, DOI 10.7860/JCDR/2017/27127.10207
· Ogunkeye O O, 2006, Pathophysiology, V13, P91, DOI 10.1016/j.pathophys.2006.01.002
· Rink M, 2012, EUR UROL, V61, P854, DOI 10.1016/j.eururo.2011.12.055
· Roach M, 2006, INT J RADIAT ONCOL, V65, P965, DOI 10.1016/j.ijrobp.2006.04.029
· Santarpia L, 2013, J CACHEXIA SARCOPENI, V4, P31, DOI 10.1007/s13539-012-0083-5
· Shariat SF, 2004, J CLIN ONCOL, V22, P1655, DOI 10.1200/JCO.2004.09.142
· Shariat SF, 2011, ACTA ONCOL, V50, P61, DOI 10.3109/0284186X.2010.542174
· Singh H, 2004, J UROLOGY, V171, P1089, DOI 10.1097/01.ju.0000112763.74119.d4
· Soliday Flanna K, 2010, AANA J, V78, P313
· Witte LPW, 2008, EUR UROL, V54, P326, DOI 10.1016/j.eururo.2007.12.007
dc.description.index MEDLINE
dc.identifier.eissn 1873-2496
hcfmusp.citation.scopus 0
hcfmusp.citation.wos 0
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Romênia
hcfmusp.affiliation.country Áustria
hcfmusp.affiliation.country Japão
hcfmusp.affiliation.country Suíça
hcfmusp.affiliation.country Jordânia
hcfmusp.affiliation.country Itália
hcfmusp.affiliation.country França
hcfmusp.affiliation.country Canadá
hcfmusp.affiliation.country Estados Unidos


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics